The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MRK | -18.45% | -13.34% | -2.82% | +1,195% |
| S&P | +13% | +86.41% | +13.26% | +1,052% |
Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $5.32B | 1.0% |
| Gross Profit | $3.21B | 2.2% |
| Gross Margin | 60.42% | 0.7% |
| Market Cap | $47.59B | -30.7% |
| Market Cap / Employee | $0.76M | -30.8% |
| Employees | 62.3K | 0.1% |
| Net Income | $898.00M | 10.6% |
| EBITDA | $1.68B | -2.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.25B | -28.8% |
| Accounts Receivable | $4.34B | 5.6% |
| Inventory | 4.5K | 2.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $10.45B | 32.6% |
| Short Term Debt | $1.65B | -52.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 5.85% | 0.5% |
| Return On Invested Capital | 8.52% | 0.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.14B | 13.5% |
| Operating Free Cash Flow | $1.52B | 4.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 21.90 | 19.53 | 16.70 | 16.10 | -36.82% |
| Price to Book | 2.15 | 1.84 | 1.60 | 1.68 | -30.01% |
| Price to Sales | 2.88 | 2.58 | 2.25 | 2.24 | -31.73% |
| Price to Tangible Book Value | 13.87 | 12.29 | 9.08 | 8.92 | -47.78% |
| Price to Free Cash Flow TTM | 32.83 | 38.87 | 42.55 | 37.77 | -13.57% |
| Enterprise Value to EBITDA | 43.78 | 38.07 | 36.43 | 34.31 | -23.18% |
| Free Cash Flow Yield | 3.0% | 2.6% | 2.4% | 2.6% | 15.71% |
| Return on Equity | 9.8% | 9.7% | 10.1% | 10.3% | 8.24% |
| Total Debt | $10.30B | $8.70B | $9.40B | $12.10B | 6.25% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
